| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| SELL | SELL | SELL | SELL | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 6.50▼ | 6.50▼ | 6.50▼ | 6.13▼ | 6.29▼ |
| MA10 | 6.52▼ | 6.52▼ | 6.52▼ | 6.40▼ | 6.08▼ |
| MA20 | 6.65▼ | 6.67▼ | 6.69▼ | 6.47▼ | 6.65▼ |
| MA50 | 6.89▼ | 6.60▼ | 6.43▼ | 6.05▼ | 10.27▼ |
| MA100 | 6.32▼ | 6.67▼ | 6.89▼ | 6.88▼ | 81.45▼ |
| MA200 | 6.95▼ | 7.22▼ | 7.80▼ | 9.31▼ | N/A |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | -0.073▼ | -0.092▼ | -0.100▼ | -0.078▼ | 0.681▲ |
| RSI | 38.332▼ | 40.330▼ | 40.044▼ | 42.279▼ | 36.341▼ |
| STOCH | 48.059 | 48.059 | 48.059 | 33.454 | 37.180 |
| WILL %R | -100.000▼ | -100.000▼ | -100.000▼ | -89.683▼ | -82.820▼ |
| CCI | -187.489▼ | -187.489▼ | -187.489▼ | -249.307▼ | -49.893 |
|
Tuesday, June 17, 2025 05:00 PM
Strategic collaboration with LaunXP for the development of vebreltinib in combination with an EGFR inhibitor (“EGFRi”) to bring in $10 million upfront payment and expand dataset to combination ...
|
|
Thursday, April 17, 2025 05:00 PM
Apollomics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to ...
|
|
Tuesday, January 21, 2025 09:40 AM
Find the latest Apollomics Inc. Class A Ordinary Shares (APLM) annual income statements, balance sheets, financial statements, ratios, and cash flow data at Nasdaq.com.
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 20/06/25 | 5.96 | 6.00 | 5.50 | 5.695 | 3,746 |
| 18/06/25 | 6.30 | 6.6981 | 5.86 | 6.06 | 4,030 |
| 17/06/25 | 6.355 | 6.355 | 6.355 | 6.355 | 656 |
| 16/06/25 | 6.355 | 6.7509 | 6.08 | 6.4744 | 2,426 |
| 13/06/25 | 6.89 | 6.89 | 6.073 | 6.073 | 3,939 |
| 12/06/25 | 6.85 | 6.92 | 6.85 | 6.92 | 2,208 |
| 11/06/25 | 6.855 | 6.9263 | 6.79 | 6.816 | 1,078 |
| 09/06/25 | 6.05 | 6.65 | 6.05 | 6.65 | 1,856 |
| 06/06/25 | 6.50 | 6.50 | 6.50 | 6.50 | 1,499 |
| 05/06/25 | 6.30 | 6.53 | 6.05 | 6.50 | 2,316 |
|
|
||||
|
|
||||
|
|